Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2

Jun-Gyu Park, Fatai S. Oladduni, Kevin Chiem, Chengjin Ye, Michael Pipenbrink, Thomas Moran, Mark R. Walter, James Kobie, Luis Martinez-Sobrido
doi: https://doi.org/10.1101/2020.07.22.216648
Jun-Gyu Park
1Texas Biomedical Research Institute, San Antonio, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fatai S. Oladduni
1Texas Biomedical Research Institute, San Antonio, TX, USA
2Department of Veterinary Microbiology, University of Ilorin, Nigeria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Chiem
1Texas Biomedical Research Institute, San Antonio, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chengjin Ye
1Texas Biomedical Research Institute, San Antonio, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Pipenbrink
3Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Moran
4Department of Microbiology, Center for Therapeutic Antibody Discovery, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark R. Walter
3Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Kobie
3Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Martinez-Sobrido
1Texas Biomedical Research Institute, San Antonio, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lmartinez@txbiomed.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Towards the end of 2019, a novel coronavirus (CoV) named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), genetically similar to severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1), emerged in Wuhan, Hubei province of China, and has been responsible of coronavirus disease 2019 (COVID-19) in humans. Since its first report, SARS-CoV-2 has resulted in a global pandemic, with over 10 million human infections and over 560,000 deaths reported worldwide at the end of June 2020. Currently, there are no United States (US) Food and Drug Administration (FDA)-approved vaccines and/or antivirals licensed against SARS-CoV-2, and the high economical and health impact of SARS-CoV-2 has placed global pressure on the scientific community to identify effective prophylactic and therapeutic treatments for the treatment of SARS-CoV-2 infection and associated COVID-19 disease. While some compounds have been already reported to reduce SARS-CoV-2 infection and a handful of monoclonal antibodies (mAbs) have been described that neutralize SARS-CoV-2, there is an urgent need for the development and standardization of assays which can be used in high through-put screening (HTS) settings to identify new antivirals and/or neutralizing mAbs against SARS-CoV-2. Here, we described a rapid, accurate and highly reproducible plaque reduction microneutralization (PRMNT) assay that can be quickly adapted for the identification and characterization of both neutralizing mAbs and antivirals against SARS-CoV-2. Importantly, our MNA is compatible with HTS settings to interrogate large and/or complex libraries of mAbs and/or antivirals to identify those with neutralizing and/or antiviral activity, respectively, against SARS-CoV-2.

Competing Interest Statement

J.G.P., F.S.O., M.P., M.W., J.K., and L.M.S. are listed as inventors on a pending patent application describing the SARS-CoV-2 antibody 1207B4.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted July 23, 2020.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2
Jun-Gyu Park, Fatai S. Oladduni, Kevin Chiem, Chengjin Ye, Michael Pipenbrink, Thomas Moran, Mark R. Walter, James Kobie, Luis Martinez-Sobrido
bioRxiv 2020.07.22.216648; doi: https://doi.org/10.1101/2020.07.22.216648
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2
Jun-Gyu Park, Fatai S. Oladduni, Kevin Chiem, Chengjin Ye, Michael Pipenbrink, Thomas Moran, Mark R. Walter, James Kobie, Luis Martinez-Sobrido
bioRxiv 2020.07.22.216648; doi: https://doi.org/10.1101/2020.07.22.216648

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Microbiology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4382)
  • Biochemistry (9591)
  • Bioengineering (7090)
  • Bioinformatics (24857)
  • Biophysics (12600)
  • Cancer Biology (9956)
  • Cell Biology (14349)
  • Clinical Trials (138)
  • Developmental Biology (7948)
  • Ecology (12105)
  • Epidemiology (2067)
  • Evolutionary Biology (15988)
  • Genetics (10925)
  • Genomics (14738)
  • Immunology (9869)
  • Microbiology (23660)
  • Molecular Biology (9484)
  • Neuroscience (50860)
  • Paleontology (369)
  • Pathology (1539)
  • Pharmacology and Toxicology (2682)
  • Physiology (4013)
  • Plant Biology (8657)
  • Scientific Communication and Education (1508)
  • Synthetic Biology (2394)
  • Systems Biology (6433)
  • Zoology (1346)